Hints and tips:
...Indivior and its subsidiary Indivior Solutions have also previously agreed to pay $600m to resolve related liabilities....
...Here’s Stifel: Under the terms of Indivior's settlement, a wholly-owned subsidiary, Solutions Inc. has pleaded guilty to one count of making a false statement relating to health matters in 2012....
...Mark Crossley, Indivior’s chief financial and operations officer, will replace Shaun Thaxter as chief executive of the pharmaceutical company....
...Shaun Thaxter, the long-serving chief executive of Indivior who abruptly left the company earlier this week, has pleaded guilty to a criminal charge in the US in connection with the marketing of Suboxone...
...Indivior shares rose on Thursday on stronger than expected sales of Suboxone, but Citi analysts said it was difficult to value the stock with a large potential fine hanging over it....
...Indivior’s patents on the treatment expire in 2024....
...Shaun Thaxter, Indivior chief executive, said: Today’s news is disappointing to Indivior, given the belief that the company has in its intellectual property for Suboxone Film....
...Indivior vowed to appeal a ruling from the US District Court for the District of Delaware, which said that a proposed generic opioid addiction treatment by Dr Reddy’s does not infringe any of Indivior’s...
...Indivior soared 36.2 per cent to 235.1p after the drugmaker won a patent trial that could keep generic versions of its Suboxone film for treating heroin addiction off the US market until 2024....
...Buprenorphine is already available in tablet form and Indivior, the London-listed pharmaceuticals group, makes a thin film version of it, called Suboxone, that dissolves under the tongue....
...announcing its intention to spin off its Duracell battery business and then selling it to Warren Buffett’s Berkshire Hathaway ● Reckitt Benckiser’s decision to float its pharmaceutical business, to be called Indivior...
International Edition